≡ Injury Lawsuit Connect ≡ Ozempic, Mounjaro & Wegovy Lawsuits

Ozempic GLP-1 NAION Vision Loss Lawsuit [2026]: NAION Vision Loss Eye Injury Cases

Ozempic, Mounjaro, Wegovy, Rybelsus GLP-1 NAION Eye Injury Vision Loss Lawsuit Cases and Settlement Claims non-arteritic anterior ischemic optic neuropathy

Have You (or a Loved One) Suffered From Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION), Sudden Vision Loss, Blindness or Other Eye Injury After Taking Ozempic or Other GLP-1 Medication?

GLP-1 NAION Vision loss Lawsuits & Settlements

Reviewed by Jacobs Kolton, Chtd. Attorneys at Law; Updated Nov. 2026

The Ozempic and GLP-1 NAION lawsuits involve claims that manufacturers of GLP-1 medications such as Ozempic, Wegovy, and Rybelsus failed to adequately warn patients and doctors about the potential risk of developing non-arteritic anterior ischemic optic neuropathy (NAION), a serious eye injury that can cause sudden vision loss, optic nerve damage, partial blindness, or permanent blindness.

Our team of drug injury attorneys and class action lawyers is investigating potential GLP-1 NAION eye injury lawsuit cases and settlement claims of individuals who were diagnosed with non-arteritic anterior ischemic optic neuropathy (NAION) and suffered sudden vision loss, blindness, optic nerve damage or other eye injury after using Ozempic or other GLP-1 receptor agonist medications.

Gastroparesis lawsuit case settlement claim Mounjaro, Wegovy, Trulicity, Rybelsus, Saxenda stomach paralysis Gastric paralysis Frozen stomach Abdominal

If you or a loved one were diagnosed with non-arteritic anterior ischemic optic neuropathy (NAION) or sudden vision loss after taking Ozempic, Wegovy, or other semaglutide or GLP-1 receptor agonist medication, you may be entitled to recover compensation from an Ozempic NAION lawsuit case or settlement claim.

Non-arteritic anterior ischemic optic neuropathy or NAION is a medical condition that involves sudden vision loss in (usually) one eye due to insufficient blood supply to the front part of the optic nerve (akin to a stroke of the optic nerve). Non-arteritic means it’s not related to inflammation of the arteries. Anterior refers to the front part of the optic nerve, where the damage occurs in NAION. Ischemic means a lack of blood supply to the tissue, which reduced blood flow to the optic nerve can lead to lack of oxygen and nutrients supply, cellular injury, tissue death and nerve damage. Optic neuropathy refers to damage or disease of the optic nerve, which carries visual information from the eye to the brain, which can result in partial or total vision loss (blindness).

According to the American Academy of Ophthalmology, the estimated annual incidence of NAION in the U.S. is between 2.3 and 10.3 people per 100,000 individuals per year, resulting in approximately 6,000 new NAION cases each year, making it the most common cause of acute optic neuropathy in patients over the age of 50.

Unfortunately, recent studies have found that the use of certain GLP-1 receptor agonist medications such as Ozempic, Wegovy, Rybelsus and other GLP-1 medications may be associated with an increased risk of developing non-arteritic anterior ischemic optic neuropathy or NAION. Following a review of the medical research and clinical trial data, on November 9, 2026 the U.S. Food and Drug Administration (FDA) issued a Drug Safety Communication announcing that it is requiring manufacturers of all GLP-1 medications, including Ozempic, Wegovy, Rybelsus, Zepbound, Mounjaro and others, to add warnings to their drug labels about this rare but serious eye condition, which can cause sudden vision loss and potentially permanent blindness.

Patients diagnosed with NAION are now coming forward and filing Ozempic GLP-1 NAION eye injury lawsuits seeking compensation and justice for the harm and suffering they may have endured.

ozempic-naion-sudden-vision-loss-lawsuit-cases

Ozempic NAION Vision Loss Lawsuits: Overview


NAION Eye Injury Lawsuit & Settlement Cases

NAION lawsuit and settlement cases potentially being investigated include claims of individuals who, after taking Ozempic, Wegovy or other semaglutide or GLP-1 medications to treat diabetes or obesity, were diagnosed with non-arteritic anterior ischemic optic neuropathy:

  • Non-arteritic anterior ischemic optic neuropathy
  • NAION
  • Non-arteritic AION
  • Ischemic optic neuropathy
  • Papillitis ischemica
  • Anterior ischemic optic neuropathy (AION):
  • Eye stroke
  • Optic disc infarction
  • Disc edema with ischemic etiology
  • Optic nerve damage
  • Sudden vision loss
  • Blindness
  • Other eye injury lawsuit cases

If you or someone you love took Ozempic, Wegovy, or other GLP-1 medications and were later diagnosed with NAION, you may qualify to recover money from an Ozempic NAION lawsuit or settlement case.

Ozempic GLP-1 NAION Eye Injury Lawsuit Cases and Settlement Claims

GLP-1 NAION Lawsuit & Settlement Updates

Updates about GLP-1 NAION lawsuits and settlements include:

  • November 2026: Federal lawsuits involving allegations of non-arteritic anterior ischemic optic neuropathy (NAION) and vision loss linked to Ozempic, Wegovy and other GLP-1 medications continue to increase. According to the U.S. Judicial Panel on Multidistrict Litigation (JPML), 278 cases were pending in the GLP-1 NAION multidistrict litigation (MDL No. 3163) as of November 2, 2026, compared with 247 cases on October 1, an increase of 31 lawsuits in one month. On November 9, 2026, the U.S. Food and Drug Administration (FDA) announced a significant new safety labeling requirement for GLP-1 medications, including Ozempic, Wegovy, Rybelsus, Mounjaro and Zepbound, following growing concerns about non-arteritic anterior ischemic optic neuropathy (NAION), a rare eye injury that can result in sudden vision loss or permanent blindness. After evaluating clinical research, adverse event reports and other medical evidence, the FDA determined that patients using GLP-1 medications may face an increased risk of developing NAION and directed drug manufacturers to include this potential danger in the Warnings and Precautions sections of their prescription labels. An FDA analysis involving 126 clinical trials identified approximately 6.4 NAION cases per 100,000 person-years among GLP-1 users, compared with 3.8 cases among patients receiving other treatments or a placebo. The FDA’s decision marks an important regulatory development as federal lawsuits alleging GLP-1-related optic nerve damage and vision loss continue in multidistrict litigation (MDL No. 3163). However, the warning does not establish that GLP-1 medications caused any particular patient’s NAION diagnosis.
  • October 2026: On October 20, 2026, U.S. District Judge Karen Spencer Marston issued Case Management Order No. 16, establishing new requirements for plaintiffs pursuing GLP-1-related NAION vision loss lawsuits in federal court. Under the order, individuals bringing claims against manufacturers of Ozempic, Wegovy, Mounjaro and other GLP-1 medications must complete detailed Plaintiff Fact Sheets and provide authorizations for obtaining relevant medical records and other supporting documentation. These requirements are designed to help attorneys and defendants evaluate individual allegations of optic nerve damage, sudden vision loss and other complications associated with NAION. The order represents another procedural step in the developing litigation as the parties gather evidence and prepare for further court proceedings, including the eventual selection of potential bellwether cases.
  • August 2026: The federal judge overseeing the growing number of GLP-1 NAION vision loss lawsuits established a detailed pretrial schedule addressing several major legal and scientific questions in the litigation. On August 27, 2026, Judge Karen Spencer Marston issued Case Management Order No. 14, setting deadlines for discovery, expert reports and motions concerning whether GLP-1 medications can cause NAION and whether manufacturers provided adequate warnings about the alleged risk. Under the schedule, fact discovery involving Eli Lilly is due to conclude in December 2026, followed by Novo Nordisk discovery in February 2027. Plaintiffs’ expert reports are due in March 2027, with motions challenging expert testimony and seeking summary judgment scheduled for July 2027. These proceedings could play an important role in determining how the NAION lawsuits advance toward potential trials and settlement discussions.
  • March 2026: On March 16, 2026, Judge Karen Spencer Marston entered an order scheduling a Science Day for June 2, 2026. Science Day allows attorneys and experts to educate the court about the medical and scientific issues involved in the GLP-1 NAION litigation.
  • December 2025: On December 15, 2025, the U.S. Judicial Panel on Multidistrict Litigation entered an order centralizing GLP-1 NAION lawsuits filed or pending in federal court for pre-trial proceedings in an MDL, styled as In Re: Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAS) Non-Arteritic Anterior Ischemic Optic Neuropathy Products Liability Litigation, MDL Case No. 3163, in the United States District Court for the Eastern District of Pennsylvania (Judge Karen S. Marston). The JPML found that the GLP-1 NAION lawsuits shared common questions of fact, including allegations that Plaintiffs’ use of certain GLP-1 RA drugs caused them to suffer from non-arteritic anterior ischemic optic neuropathy (NAION). The GLP-1 NAION litigation is being handled separately from the earlier GLP-1 gastrointestinal injury MDL.
  • August 2025: As more GLP-1 vision loss lawsuits were filed, parties asked the U.S. Judicial Panel on Multidistrict Litigation to centralize NAION cases. The proposed litigation involved claims that GLP-1 medications caused non-arteritic anterior ischemic optic neuropathy and that manufacturers failed to properly warn about this alleged risk.
  • Late 2024 to 2025: After a GLP-1 NAION study was published potentially linking semaglutide GLP-1 medications to a higher risk of developing NAION, lawsuits and investigations began focusing on whether manufacturers failed to adequately warn about the risk of sudden vision loss, optic nerve damage, and permanent blindness.

Several recent studies have found a potential link between semaglutide (the active ingredient in Ozempic, Wegovy and Rybelsus) and non-arteritic anterior ischemic optic neuropathy (NAION), including:

Medical Study or WarningSummary
British Journal of Ophthalmology, Lakhani et al., “Ischaemic optic neuropathy with semaglutide: global observational analysis of sex- and formulation-specific risk,” March 2026This global pharmacovigilance study analyzed 30 million reports from the FDA Adverse Event Reporting System (2017–2024) and found that ischemic optic neuropathy was reported about 18.8 times more often with Ozempic and 74.89 times more often with Wegovy than expected based on reporting patterns for other drugs/adverse events in the database.
JAMA Ophthalmology, Heberer et al., “New-Onset Nonarteritic Anterior Ischemic Optic Neuropathy and Initiators of Semaglutide in US Veterans With Type 2 Diabetes,” 2026In a nationwide cohort of U.S. veterans with type 2 diabetes, semaglutide initiators had a 2.33-fold higher NAION risk than SGLT2 inhibitor initiators.
MHRA Drug Safety Update, February 2026The UK Medicines and Healthcare products Regulatory Agency warned that NAION has been reported with semaglutide used for type 2 diabetes, weight management and cardiovascular risk reduction. MHRA advised urgent ophthalmology referral for sudden or partial vision loss and discontinuation of semaglutide if NAION is confirmed.
JAMA Ophthalmology, Hsu et al., “Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy,” 2025This cohort study that analyzed health records of over 37 million people with type 2 diabetes found that semaglutide use was associated with increased NAION risk in patients with diabetes at the 2-year, 3-year, and 4-year time points. Researchers found that patients on semaglutide had a 32% increased relative risk of developing NAION compared to those not taking the drug. The study also found that semaglutide users did not have a significantly increased risk compared to users of other GLP-1 medications, suggesting the possibility that other GLP-1 medications may also be linked to an increased risk of NAION.
Medical Study or Warning Summary
JAMA Ophthalmology, Hathaway et al., “Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide,” 2024
This matched cohort study found a potential association between semaglutide use and increased NAION risk. The reported hazard ratio was 4.28 among patients with type 2 diabetes and 7.64 among patients who were overweight or obese.
University of Southern Denmark / Danish and Norwegian Cohort Studies, 2024Researchers analyzing Danish and Norwegian diabetes patients reported that Ozempic or semaglutide use was associated with approximately double the risk of developing NAION compared with other diabetes medications.

On November 9, 2026, the FDA announced that it is requiring new safety warnings for Ozempic, Wegovy, Mounjaro, Zepbound, Rybelsus and other GLP-1 medications due to a potential increased risk of non-arteritic anterior ischemic optic neuropathy (NAION), a serious eye condition that can cause sudden vision loss or permanent blindness.

The FDA is directing manufacturers to add information about the potential risk of NAION to the Warnings and Precautions sections of their prescription drug labels. The decision follows a comprehensive safety review involving clinical trials, medical studies, adverse event reports and other evidence examining the possible connection between GLP-1 medications and optic nerve damage.

As part of its investigation, the FDA analyzed data from 126 clinical trials involving more than 134,000 patients. The agency identified a higher rate of NAION among patients receiving GLP-1 medications, with approximately 6.4 cases per 100,000 person-years compared to 3.8 cases among patients receiving placebo or other non-GLP-1 diabetes treatments. Although NAION remains rare, the FDA concluded that the available evidence supports warning patients and healthcare providers about the potential increased risk.

The FDA also advised patients to seek immediate medical attention if they experience sudden, painless vision loss, blurred vision, blind spots or other unexpected changes in their eyesight. Patients diagnosed with NAION should consult their healthcare provider about whether to continue taking their GLP-1 medication.

The FDA’s decision represents a significant development in the ongoing Ozempic and GLP-1 NAION vision loss litigation, where patients allege that drug manufacturers failed to adequately warn about the potential risk of serious eye injuries.

NAION Signs & Symptoms

NAION signs and symptoms can potentially include:

  • Sudden vision loss in one eye
  • Painless loss of vision
  • Monocular vision loss
  • Visual field defects
  • Dark or shadowy areas in vision
  • Altitudinal field defect
  • Loss of vision in lower half of visual field
  • Loss of vision in upper half visual field
  • Blind spot in center of field of vision (central scotoma)
  • Loss of vision in the outer parts of the visual field
  • Peripheral vision loss
  • Pale optic nerve head
  • Pallor of the optic disc
  • Optic disc edema (optic disc swelling)
  • Optic nerve swollen
  • Optic atrophy
  • Optic nerve fibers degenerate
  • Decreased visual acuity
  • Reduction sharpness of vision
  • Blood vessel abnormalities
  • Peripapillary hemorrhage (bleeding)
  • Optic disc hemorrhage
  • Decreased color vision
  • Absence of inflammation of the eye
  • Afferent pupillary defect (APD) / Marcus Gunn Pupil
  • Other NAION symptoms or signs

Procedures and tests used by ophthalmologists (or neuro-ophthalmologists) to diagnose NAION can include a comprehensive eye exam (including visual acuity, color vision testing, pupil examination for an afferent pupillary defect, and dilated funduscopic examination to view the optic nerve), visual field testing, optical coherence tomography (OCT) of the optic nerve head and retinal nerve fiber layer, fluorescein angiography to assess optic nerve blood flow and blood tests to rule out other conditions.

NAION Complications

Complications from NAION can potentially include:

  • Permanent vision loss
  • Optic nerve atrophy
  • Long-term vision impairment
  • Blurred or foggy vision
  • Seeing dark shadows
  • Increased sensitivity to light
  • Progressive vision loss in the other eye
  • Cognitive impairment
  • Psychosocial impact
  • Emotional distress
  • Depression
  • Anxiety
  • Reduced quality of life due to impaired vision
  • Chronic eye fatigue
  • Strain in the remaining functional eye
  • Headaches
  • Other NAION eye injury complications

NAION Treatments

There is currently no proven cure for NAION, and treatment options are limited. Depending on the patient’s condition, doctors may focus on managing vascular risk factors, monitoring the affected and unaffected eye, and evaluating possible interventions on a case-by-case basis such as prescribing medication such as corticosteroids (e.g., prednisone) to reduce inflammation and improve blood flow to the optic nerve, anticoagulants (e.g., aspirin) to help prevent blood clots that could block blood flow to the optic nerve and angiogenesis inhibitors (e.g., bevacizumab) to try to block the growth of abnormal blood vessels that can damage the optic nerve; and optic nerve decompression surgery to try to relieve pressure on the optic nerve.

If you or a loved one were diagnosed with non-arteritic anterior ischemic optic neuropathy or NAION after taking Ozempic, Wegovy, semaglutide or other GLP-1 receptor agonist medications, you may be entitled to compensation from a NAION lawsuit or settlement. Contact a drug injury lawyer to request a free case review.

*If you or a loved one are experiencing health issues, side effects or complications after taking a prescription drug or medication, we urge you to promptly consult with your doctor or physician for an evaluation.

**The listing of a company (e.g., Novo Nordisk, Eli Lilly) or product (e.g., Ozempic, Mounjaro, Wegovy, Rybelsus, Trulicity, Saxenda or Zepbound) is not meant to state or imply that the company acted illegally or improperly or that the product is unsafe or defective; rather only that an investigation may be, is or was being conducted to determine whether legal rights have been violated.

***The use of any trademarks, tradenames or service marks is solely for product identification and/or informational purposes.

Fill out the form to request a free attorney review.